LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles

LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.